Skip to main content

Table 1 Characteristics of included trials

From: Efficacy and safety of Tripterygium wilfordii hook F for chronic urticaria: a systematic review and meta-analysis

Study (author/year)

Sample size (I/C)

Average courses (\( \overline{\mathrm{X}} \)[SD])

Interventions

Course of treatment

Used instruments in the study

T

C

T

C

Pi 2006 [13]

21/22

1.30 [2.03] y

TG + Mizolastine

Mizolastine

≤12 w

LFS, SSRI, ADE

Zhang 2007 [14]

86/82

0.85 y

TwHF + Levocetirizine

Levocetirizine

4 w

LFS, SSRI, ADE

Bao 2008 [15]

87/80

1.60 y

GTT + Desloratadine

Desloratadine

4 w

LFS, SSRI, ADE

Xu2009 [16]

54/54

1.08 y

1.17 y

TG + Desloratadine

Desloratadine

4 w

LFS, SSRI, ADE, RER

Wei 2010 [17]

90/90

6.25 y

6.20 y

GTT + Desloratadine

Desloratadine

4 w

LFS, SSRI, ADE, DLQI

Zhong 2011 [18]

40/38

16.75 y

16.25 y

THH + Cetirizine Hydrochloride

Placebo + Cetirizine Hydrochloride

4 w

LFS, TER, ADE

Liu 2011 [19]

98/90

16.20 [0.96] y

GTT + Levocetirizine Hydrochloride

Levocetirizine Hydrochloride

4 w

LFS, SSRI, ADE

Qian 2011 [9]

180/180

6.72 [3.47] y

6.51 [3.76] y

TG + Loratadine; TG + Mizolastine; TG + Cetirizine

Loratadine; Mizolastine; Cetirizine

4 w

LFS, UAS,S SRI, ADE, DLQI, RER

Yu 2011 [20]

48/47

1.7 y

THH + Terfenadine

Terfenadine

4 w

SA, ADE

Lu 2012 [21]

40/40

3.20 [1.60] y

3.20 [1.20] y

TG + Fexofenadine hydrochloride

Fexofenadine hydrochloride

4 w

LFS, SSRI, ADE

Zhou 2012 [22]

60/60

3.97 [2.97] y

3.45 [2.72] y

THH + Mizolastine + Ketotifena

Mizolastine + Ketotifena

8 w

UAS, SSRI, ADE

Fan 2013 [23]

43/41

2.70 y

2.77 y

GTT + Ebastine

Ebastine

4 w

LFS, SSRI

Liu 2013 [24]

89/90

≥0.13 y

TG + Cetirizine Hydrochloride

Cetirizine Hydrochloride

4 w

LFS, VAS, SSRI, ADE, RER

Zheng 2013 [25]

37/37

≥0.13 y

GTT + Desloratadine

Desloratadine

4 w

LFS ,SSRI, ADE,DLQI, RER

Chen 2014 [26]

45/46

3.70 [1.30] y

3.90 [1.10] y

GTT + Fexofenadine

Fexofenadine

4 w

UAS, VAS, LFS, ADE

Wang 2014 [27]

32/32

≥0.13 y

GTT + Desloratadine

Desloratadine

4 w

SA, ADE

Zhou 2014 [28]

60/60

≥0.13 y

GTT + Desloratadine

Desloratadine

4 w

LFS, SSRI, ADE, RER

Li 2016 [29]

36/34

≥0.13 y

TG + Ebastine

Ebastine

4 w

SA, ADE

Liu 2016 [30]

60/60

0.53 [0.27] y

0.58 [0.33] y

GTT + Desloratadine

Desloratadine

4 w

LFS, SSRI, ADE, DLQI

Chen 2017 [31]

45/45

0.56 [0.32] y

0.53 [0.27] y

GTT + Desloratadine

Desloratadine

4 w

SA, ADE

Tao 2017 [32]

48/49

2.46 [0.52] y

2.53 [0.63] y

GTT + Desloratadine

Desloratadine

4 w

LFS, SSRI, ADE, DLQI, RER

  1. aAdministered ketotifen for 4 weeks
  2. TwHF Tripterygium wilfordii Hook F, GTT Glucosidorum Tripterygll Totorum, TG Tripterygium Glycosides, THH Tripterygium hypoglaucum (levl.) Hutch, LFS Four-level Score Method, UAS Urticaria Activity Score, SSRI Symptom Score Reduce lndex, ADE Adverse Events, DLQI Dermatology Life Quality Index, RER Recurrence Rate, TER Total Effective Rate, VAS Visual Analogue Scales, SA Symptom Assessment